TY - JOUR AB - Ovarian cancer is the third most common type of gynecological tumor, in addition to being the most lethal. Cytoreductive surgery with chemotherapy is the standard treatment for ovarian cancer. It is necessary to identify novel chemotherapeutic methods, since current chemotherapy treatments are rarely effective for patients with advanced‑stage or recurrent ovarian cancer and may cause acute systemic toxicity. Icariin (ICA) is a prenylated flavonol glycoside derived from Herba Epimedii, a medicinal plant with a variety of pharmacological activities, including anticancer, antidiabetic and anti‑obesity effects. By analyzing cell viability, cell cycle and cell migration, the present study demonstrated that ICA inhibited the cell viability of the ovarian cancer cell line, SKOV3, and blocked cell cycle transition. ICA inhibited the expression of fuse binding protein 1 (FBP1), a critical regulator of proliferation and tumorigenesis through binding to the c‑Myc promoter, as well as β‑catenin, a key regulator in ovarian cancer initiation, metastasis, chemoresistance and recurrence. Furthermore, it was indicated that ICA inhibited the migration of SKOV3 cells. In accordance with our previous findings on high FBP1 expression in ovarian cancer, FBP1 was a potential target of ICA in ovarian cancer cells. Based on these results, the present study demonstrated that ICA may be a potential therapeutic agent for ovarian cancer treatment. AD - Guangzhou Institute of Traumatic Surgery, Guangzhou Red Cross Hospital, Jinan University School of Medicine, Guangzhou, Guangdong 510632, P.R. China Department of Surgery, Guangzhou Red Cross Hospital, Jinan University School of Medicine, Guangzhou, Guangdong 510632, P.R. China AU - Wang,Pengzhen AU - Zhang,Jinli AU - Xiong,Xifeng AU - Yuan,Wei AU - Qin,Shengnan AU - Cao,Wenjuan AU - Dai,Libing AU - Xie,Fuqin AU - Li,Aiguo AU - Liu,Zhihe DA - 2019/04/01 DO - 10.3892/or.2019.6986 EP - 2328 IS - 4 JO - Oncol Rep KW - icariin ovarian cancer cell cycle metastasis PY - 2019 SN - 1021-335X 1791-2431 SP - 2321 ST - Icariin suppresses cell cycle transition and cell migration in ovarian cancer cells T2 - Oncology Reports TI - Icariin suppresses cell cycle transition and cell migration in ovarian cancer cells UR - https://doi.org/10.3892/or.2019.6986 VL - 41 ER -